Scilex (SCLX) Bio, a controlling interest of joint venture by Scilex Holding Company, announced the signing of a binding term sheet with NeuroBiogen to grant Scilex Bio an exclusive worldwide license to the franchise KDS2010 drug candidate to develop and commercialize in metabolic diseases and neurodegenerative diseases, including Alzheimer’s, Parkinson’s and other CNS diseases. The lead program in the proposed joint venture is an oral tablet product candidate that is currently in Phase 2 trials in obesity and Alzheimer’s disease indications. The term sheet provides that NeuroBiogen will grant Scilex Bio the worldwide license rights along with the rights to sublicense for all KDS2010 indications.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SCLX:
- Scilex enters binding term sheet for joint venture with IPMC
- Scilex receives Nasdaq notice of non-compliance
- Scilex Holding Plans Merger to Boost Semnur Value
- Scilex announces successful end of Phase II meeting with FDA
- Scilex Holding Sets Dividend for Preferred Stock Exchange
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
